Medexus Pharmaceuticals (TSE:MDP) PT Set at C$8.25 by Leede Financial

Medexus Pharmaceuticals (TSE:MDP) has been given a C$8.25 target price by stock analysts at Leede Financial in a research note issued to investors on Monday, MarketBeat reports. The firm presently has a “speculative buy” rating on the stock. Leede Financial’s price objective indicates a potential upside of 219.77% from the company’s previous close.

A number of other analysts have also recently commented on MDP. Stifel Nicolaus lifted their price target on Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Stifel Canada raised Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Monday, August 12th. Finally, Ventum Cap Mkts raised Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, June 26th. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of C$5.25.

Medexus Pharmaceuticals Price Performance

Shares of MDP stock opened at C$2.58 on Monday. Medexus Pharmaceuticals has a 1-year low of C$1.44 and a 1-year high of C$3.39. The stock’s fifty day moving average price is C$2.45 and its 200 day moving average price is C$1.99. The company has a market cap of C$63.29 million, a price-to-earnings ratio of 51.60 and a beta of 1.95.

Medexus Pharmaceuticals (TSE:MDP) last announced its earnings results on Wednesday, August 7th. The company reported C$0.11 earnings per share for the quarter, topping the consensus estimate of C$0.04 by C$0.07. Medexus Pharmaceuticals had a return on equity of 3.95% and a net margin of 1.00%. The firm had revenue of C$37.33 million for the quarter, compared to the consensus estimate of C$36.95 million. As a group, equities research analysts anticipate that Medexus Pharmaceuticals will post 0.1626066 earnings per share for the current year.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.